Clearside Biomedical

Clearside Biomedical Stock-Based Compensation

Delisted

The Stock-Based Compensation (SBC) of Clearside Biomedical (CLSD) as of Nov 20, 2026 is 3.48 M USD. In the previous year, Stock-Based Compensation (SBC) was 4.20 M USD — a change of -17.14% (lower).

Stock-Based Compensation

3.48 MUSD

YoY

-17.14%

Last updated:

Stock-Based Compensation (SBC) of Clearside Biomedical is 2024 3.48 M USD. Stock-Based Compensation (SBC) of Clearside Biomedical was 2023 4.20 M USD. It decreases by -17.14% lower compared to the previous year.

The Clearside Biomedical Stock-Based Compensation history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Stock-Based Compensation
Date
Stock-Based Compensation
Jan 1, 2017
3.36 M USD
Jan 1, 2018
4.79 M USD
Jan 1, 2019
4.61 M USD
Jan 1, 2020
3.60 M USD
Jan 1, 2021
5.05 M USD
Jan 1, 2022
4.88 M USD
Jan 1, 2023
4.20 M USD
Jan 1, 2024
3.48 M USD
The Clearside Biomedical Stock-Based Compensation history
YEARStock-Based CompensationYoY
3.48 MUSD-17.14%
4.20 MUSD-13.93%
4.88 MUSD-3.37%
5.05 MUSD+40.28%
3.60 MUSD-21.91%
4.61 MUSD-3.76%
4.79 MUSD+42.56%
3.36 MUSD+156.49%
1.31 MUSD+87.14%
700,000.00USD+62.79%
430,000.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Clearside Biomedical Stock analysis

What does Clearside Biomedical do? Clearside Biomedical, Inc. generates revenue through the development of drug therapies for blinding eye diseases, targeting the retina, choroid, and sclera. The company’s lead product candidate, XIPERE, is a proprietary, preservative-free suspension of the corticosteroid triamcinolone acetonide administered via suprachoroidal injection. This clinical stage biopharmaceutical firm focuses on treating conditions affecting these specific eye components to restore or preserve vision. The business model relies on advancing its proprietary therapies through clinical development rather than immediate commercial sales. By concentrating on the retina, choroid, and sclera, Clearside Biomedical, Inc. addresses critical anatomical areas involved in visual health. The company operates from its headquarters in Alpharetta, Georgia, with a dedicated team supporting its research and development efforts. Financial viability is tied to the successful progression of its drug candidates, particularly XIPERE, which utilizes a unique delivery method for triamcinolone acetonide. The firm engages in the biopharmaceutical sector by developing treatments for diseases that impact the structural and functional integrity of the eye. Its strategy centers on innovation in drug formulation and administration to treat blinding conditions effectively. Clearside Biomedical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Clearside Biomedical stock

Stock-Based Compensation (SBC) of Clearside Biomedical is 3.48 M USD in 2024.

Stock-Based Compensation (SBC) of Clearside Biomedical changed from 4.20 M USD to 3.48 M USD, representing a -17.14% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Stock-Based Compensation (SBC) Clearside Biomedical since 2006 – with annual values, charts, and detailed analysis.

Stock-based compensation is a non-cash expense representing equity awards to employees. High SBC can dilute existing shareholders and inflate reported cash flow.

Stock-Based Compensation (SBC)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Stock-Based Compensation (SBC)'s Clearside Biomedical historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Clearside Biomedical

All Key Metrics — Clearside Biomedical